Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 13/20 | 0.44 |
| ▸ | F13A1 | P00488 | 10/20 | 0.44 |
| ▸ | TGM1 | P22735 | 7/20 | 0.44 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2391300 | 0.96 | TGM2 (0.45) | TGM2F13A1TGM1TGM3MEN1 | |
| SCHEMBL1710700 | 0.86 | KMT2A (0.40) | MEN1KMT2AGAAEPHX2 | |
| SCHEMBL1710318 | 0.81 | PKM (0.43) | MEN1KMT2AGAAEPHX2 | |
| SCHEMBL14490213 | 0.81 | TGM2 (0.59) | TGM2F13A1TGM1TGM3MEN1 | |
| SCHEMBL14490211 | 0.81 | TGM2 (0.61) | TGM2F13A1TGM1TGM3MEN1 | |
| SCHEMBL2398197 | 0.79 | NR1H2 (0.38) | — | |
| SCHEMBL12259605 | 0.78 | EPHX2 (0.45) | EPHX2 | |
| SCHEMBL14490210 | 0.78 | TGM2 (0.59) | TGM2F13A1TGM1 | |
| SCHEMBL12259618 | 0.78 | FPR2 (0.41) | TGM2F13A1TGM1TGM3MEN1 | |
| SCHEMBL12259606 | 0.77 | JAK2 (0.40) | GAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | SDHA, NQO1, CYP3A5 | TGM2 1801/4885F13A1 3933/4885TGM1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.